Stockreport

US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results [Yahoo! Finance]

ADC Therapeutics SA Common Shares  (ADCT) 
PDF It was a pretty bad result overall; while revenues were in line with expectations at US$70m, statutory losses exploded to US$2.94 per share. Earnings are an important ti [Read more]